Connect with us

Press Release

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Published

on

–News Direct–

By Meg Flippin, Benzinga

Theriva Biologics (AMEX: TOVX), the clinical-stage immuno-oncology company developing therapies for difficult-to-treat cancers, hit several milestones during 2023, potentially positioning it for a strong year ahead.

That could be good news for patients with pancreatic, retinoblastoma, head and neck, brain or ovarian cancers. If Theriva is right, its oncolytic viruses can overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Its developmental therapies are designed to enable systemic delivery which means they can target the tumor and distant metastases and have the potential to enhance current standard-of-care therapies, the company says. Therivas oncolytic viruses can be administered intravenously or as a direct injection into the tumor or tumor compartment.

Trials Underway

Announcing its financial results for the full year 2023, Theriva reported ending the year in a good position with VCN-01, its lead therapy candidate. VCN-01 is currently in a phase 2b trial for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) and in investigator-sponsored studies in a number of indications. As of late March, dosing was underway and enrollment continues to progress for VIRAGE, the randomized, controlled, multicenter open-label phase 2b trial of VCN-01 in combination with standard-of-care chemotherapy as a first-line therapy in newly diagnosed metastatic PDAC patients.

The trial is targeting enrollment of 92 evaluable patients and the company reports it's on track to complete enrollment in the first half of this year. Patients are being enrolled in six sites in the U.S. and nine in Spain and will continue without any changes to the protocol after an evaluation by the Independent Data Monitoring Committee (IDMC) found no safety concerns.

Intravenous VCN-01 has been well tolerated and demonstrated a safety profile consistent with prior clinical trials, Theriva reports. Importantly, it said no additional toxicities were observed in patients receiving a second dose of VCN-01. That means repeated systemic dosing of VCN-01 is feasible from a safety perspective, paving the way for Theriva to focus on whether the repeated dose VCN-01 regimen may lead to improved clinical outcomes for patients.

We believe VCN-01s differentiated mechanism of action has the potential to address the urgent need for new treatment options for patients with PDAC by degrading the tumor matrix and increasing tumor access by VCN-01 and co-administered cancer therapies, said Theriva CEO Steven Shallcross during a conference call to discuss full year 2023 earnings. To date, more than 100 patients have been dosed with VCN-01 in clinical trials in patients with a broad range of cancers, including PDAC, retinoblastoma, colorectal cancer and head and neck squamous cell carcinoma (HNSCC). Additional investigator-sponsored studies have been initiated in patients with brain cancers and ovarian cancers.

Beyond Pancreatic Cancer

Treating pancreatic cancer with VCN-01 isnt the only area Theriva focused on during the year. The company is also engaged in a phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma. That trial is making progress, with the company completing patient treatment. The trial is designed to evaluate escalating doses of VCN-01 administered by two intravitreal injections separated by 14 days. The investigator-sponsored phase 1 trial will complete patient follow-up in the first half of 2024, and the results will help inform the planned phase 2 trial design, Theriva says. Additionally, the University of Pennsylvania continues to enroll and treat patients in their phase 1 investigator-sponsored trial administering VCN-01 with huCART-meso cells to patients with ovarian or pancreatic cancers. VCN-01 is designed to increase tumor immunogenicity and improve access by additional therapies such as huCART-meso cells.

Dosing is also underway for the ongoing phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). Theriva said SYN-004 appears to be well tolerated.

Collaborating And Expanding Partnerships

Not one to rest, Theriva was also busy during the year expanding collaborations and identifying new areas that may benefit from VCN-01. Late last year it signed an exclusive option to license intellectual property from Sant Joan de Du-Barcelona Childrens Hospital (SJD) to explore the therapeutic potential of VCN-01 in combination with topoisomerase I inhibitors. This strengthens a long-term research collaboration with SJD and builds on an ongoing trial evaluating VCN-01 in pediatric cancers.

The company is also pursuing licensing discussions for its SYN-020 intestinal alkaline phosphatase asset. SYN-020 is a recombinant bovine intestinal alkaline phosphatase (IAP) formulated for oral delivery to the small intestine and designed to diminish fat absorption and intestinal inflammation, tighten the gut barrier to mitigate leaky gut and promote a healthy microbiome. It has the potential to become a multi-indication therapeutic capable of addressing disorders stemming from gastrointestinal (GI) inflammation. Theriva is doing all this and keeping costs down. For the year ended December 31, 2023, general and administrative expenses decreased 28% to $7.1 million from $9.9 million in the year-earlier period. Meanwhile, the company increased spending on research and development by 22%, with an eye on the future based on an observed uptick in demand for its compounds.

In 2023, we continue to make steady progress to drive forward our oncology-focused portfolio designed to address unmet needs for difficult-to-treat cancers, said Shallcross on the earnings call. Our primary efforts and resources are focused on pursuing multiple therapeutic opportunities for our lead clinical candidate VCN-01. We'll continue to look for ways to drive additional value for our shareholders and for the long-term success of what we're trying to do, namely delivering promising treatments for very, very difficult-to-treat cancers.

Featured photo by National Cancer Institute on Unsplash.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Benzinga

+1 877-440-9464

[email protected]

Company Website

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/theriva-biologics-hits-several-milestones-in-2023-positioning-itself-for-growth-as-the-firm-targets-difficult-to-treat-cancers-459618184

Benzinga

comtex tracking

COMTEX_450971675/2655/2024-04-17T08:34:28

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Rising Star: The Journey of Foday Sillah

Published

on

 

 

In the gritty world of boxing, where determination and talent collide in the ring, a new contender has emerged, captivating audiences with raw skill and unwavering spirit. Foday Sillah, a rising star in the boxing scene, is poised to make a lasting mark on the sport with his remarkable journey from humble beginnings to the cusp of greatness.

Born Freetown, Sierra Leone to a Chiefdom Family and raised in Washington DC, Foday Sillah discovered his passion for boxing at the age of 19. Growing up in a Suburban Neighborhood in Northern Virginia, he found solace and purpose in the discipline of the sport. Under the guidance of his coach, Anthony Hamilton, he honed his craft, spending countless hours perfecting his technique and conditioning his body for the challenges ahead.

 

 

Despite facing numerous setbacks and obstacles along the way, Foday Sillah remained undeterred in his pursuit of greatness. His relentless work ethic and unwavering determination earned him recognition in the amateur Kickboxing circuit, where he quickly gained a reputation as a force to be reckoned with. With a Record of 24-3 and 20 knockouts, his confidence soared, fueling his ambition to compete at the highest levels of the sport.

As Foday Sillah transitioned to the professional ranks, he faced a new set of challenges, including seasoned opponents and heightened expectations. However, he embraced the pressure, viewing each fight as an opportunity to showcase his skills and prove his worthiness as a contender. With each bout, he displayed a unique blend of speed, power, and tactical brilliance. Knocking Out all of his opponents in minutes, earning the respect of fans and fellow competitors alike.

But it was not just his prowess in the ring that captured the hearts of spectators; it was also his humility and resilience in the face of adversity. Despite his rising fame, Sillah remained grounded, never forgetting his roots or the sacrifices that had brought him to where he stood today. Whether celebrating victory or enduring defeat, he approached each moment with grace and humility, embodying the true spirit of a champion.

As Foday continues his ascent in the boxing world, his future shines brightly with promise and potential. With each fight, he inches closer to his ultimate goal of becoming the First Sierra Leonean American world champion, inspiring countless others along the way to pursue their dreams with unwavering determination and unwavering courage.

In an era defined by uncertainty and upheaval, Foday Sillah stands as a beacon of hope and inspiration, proving that with passion, perseverance, and unwavering belief in oneself, anything is possible. Watch closely as this rising star blazes a trail of glory through the world of boxing, leaving an indelible mark on the sport for generations to come. 

 

Media Contact

Organization: TAC Boxing

Contact Person: Anthony Hamilton

Website: https://www.instagram.com/kingfo101/

Email: Send Email

City: Los Angeles

Country:United States

Release id:12261

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

A Gripping Tale of Justice: “Kristoff” Captivates Readers with Miami Mayhem

Published

on

A rising star in the law enforcement fiction genre, Chase Lloyd’s novel “Kristoff” is taking readers by storm. The story follows a young police trainee in Miami, Florida, whose life takes a tragic turn when a seemingly ordinary dinner descends into violence.

Driven by grief and a burning desire for justice, the protagonist pledges to become a police officer. Lloyd masterfully portrays the emotional rollercoaster of loss and determination, leaving readers invested in his character’s quest. The story details every moment of his journey to achieve justice for his irreversible loss.

“Kristoff” breathes new life into the classic revenge narrative with a unique twist.  As the investigation unfolds, the protagonist uncovers a web of deceit, with shocking revelations about his family and even potential corruption within the police force.

While the themes of death and violence may not be suitable for younger readers, “Kristoff” will undoubtedly appeal to those aged 14 and above who enjoy gripping dramas, thrillers, and classic crime fiction.

About the Author

Chase Lloyd, a screenwriter and actor, brings a wealth of experience to the page.  Equipped with a Bachelor of Arts in English (Creative Writing) and a minor in Criminal Justice, Lloyd blends his understanding of storytelling with an insider’s perspective on the world of law enforcement. His dedication to his craft extends beyond writing, as he actively hones his acting skills and participates in workshops to further refine his artistic abilities.

Contact

For inquiries or interview requests regarding “Kristoff,” please contact:

Contact: Chase Lloyd

Email: [email protected]

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

SignalPeak Offers a Comprehensive Crypto Trading Guide, Empowering Investors with Expert Insights and Timely Signals

Published

on

Summary: SignalPeak, a leading premier platform in the crypto trading landscape, has provided expert guidance and precise signals for success in cryptocurrency trading.

In the latest record, SignalPeak offers a comprehensive crypto trading guide that empowers investors with expert insights and timely signals. The platform aims to provide access to 200+ premier Telegram channels and enable individuals to get real-time crypto trading signals directly from their accounts. The platform designed these signals to enable them to make informed trading decisions.

By gaining access to over 200 elite sources, the platform offers unique market insights and trading strategies that allow individuals to trade anytime, anywhere. In addition, SignalPeak has the ability to manage all exchange platforms that individuals prefer, such as Binance, Bybit, or others, and ensure that trading is executed seamlessly. The platform gives the opportunity to select the plan that suits their trading needs and gain access to 200+ Telegram channels that are clear and easy to follow, leading to profitable trades time and time again. 

Including more, the platform aims to provide timely signals that capture market opportunities as they arise as the frequency of the signals differ based on market conditions as well as trading opportunities, ensuring they get timely updates to support their trading decisions.

Moreover, SignalPeak strives to provide high-quality signals that allow subscribers to succeed in the ever-evolving world of cryptocurrency trading. To become a subscriber, the individuals follow three steps to begin their journey towards profitable trading including:

  • Subscribe – The individuals can choose a plan according to their needs and trading goals and then be able to sign up for a premier plan.
  • Receive Signals – By joining the 200+ Telegram channels, individuals can get signals directly, accompanied by expert analysis and insights.
  • Execute Trading – The subscribers act on signals with confidence and receive profitable trading.

For the subscription plan, the platform accepts crypto payments on various cryptocurrencies such as Bitcoin, Ethereum and others. By using crypto payments, the platform aims to provide a secure and convenient payment solution for its subscribers. 

About SignalPeak:

SignalPeak has emerged as a premier platform in the crypto trading landscape, offering expert guidance and precise signals for success in cryptocurrency trading. Danny Smith appoints the Chief Marketing Officer (CMO) to drive strategic growth initiatives. With unwavering dedication, the platform continues to push the boundaries of innovation.

https://www.signalpeak.io/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST